Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.02M | $6.00K | — | $20.9M | $7.34M | $102M | $113M | $106M | $117M |
| Revenue growth | — | — | -99.4% | — | — | -65.0% | 1294.0% | 10.9% | -6.8% | 10.2% |
| Gross profit | — | — | — | — | — | — | $97.5M | $109M | $102M | — |
| Gross margin | — | — | — | — | — | — | 95.3% | 95.9% | 96.3% | — |
| Operating income | -$20.4M | -$21.8M | -$33.8M | -$57.3M | -$57.4M | -$87.9M | $9.20M | -$67.2M | $16.2M | $11.5M |
| Operating margin | — | -2143.6% | -563700.0% | — | -273.9% | -1197.8% | 9.0% | -59.3% | 15.3% | 9.9% |
| Net income | -$16.9M | -$21.6M | -$30.1M | -$55.2M | -$56.2M | -$87.9M | $4.31M | -$85.5M | $17.9M | $9.88M |
| Net margin | — | -2118.0% | -500916.7% | — | -268.5% | -1198.3% | 4.2% | -75.3% | 16.9% | 8.5% |
| EPS (diluted) | -$21.75 | -$7.45 | -$2.68 | -$4.60 | -$2.93 | -$2.87 | $0.03 | -$1.41 | $0.05 | $0.02 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.5M | -$19.9M | -$28.6M | -$43.6M | -$55.0M | -$83.8M | $10.7M | $25.9M | -$3.64M | $1.01M |
| Capital expenditures | $468K | $23.0K | $376K | $64.0K | — | $839K | $4.99M | $8.52M | $2.31M | $1.19M |
| Free cash flow | -$18.9M | -$20.0M | -$28.9M | -$43.7M | — | -$84.6M | $5.69M | $17.4M | -$5.96M | -$180K |
| Dividends paid | — | — | — | — | — | — | $45.0M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.3M | $14.5M | $31.2M | $15.4M | $30.4M | $44.3M | $25.2M | $33.5M | $11.8M | $37.1M |
| Total assets | $38.1M | $39.5M | $125M | $98.6M | $94.8M | $55.7M | $84.8M | $117M | $125M | $166M |
| Total liabilities | $22.0M | $8.74M | $4.97M | $30.2M | $18.8M | $14.6M | $12.5M | $38.1M | $27.0M | $23.9M |
| Shareholders' equity | $16.1M | $30.8M | $120M | $68.3M | $76.1M | $41.1M | $42.5M | -$15.8M | $63.3M | $106M |
| Retained earnings | -$148M | -$173M | -$203M | -$259M | -$315M | -$403M | $7.39M | -$85.5M | -$73.5M | -$68.4M |
| Shares (wtd avg diluted) | 802K | 6.08M | 12.0M | 12.0M | 22.1M | 30.6M | 75.7M | 65.8M | 102M | 103M |
Every figure is extracted from GYRE THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.